The effect of recombinant human interferon α1b treatment of infants hospitalized with lower respiratory tract infection on subsequent wheezing
Autor: | Shaofeng Song, Hui Shan, Jing Chen, Ming Li, Xue Xue, Li Zhao, Lusheng Huang, Liao Li, Xiaocui Sheng, Jianxin Xiong, Haiming Yu, Hong Cao, Lin Zhao, Chengxiu Wang, Lihua Yang, Shuhua An, Yanqi Su, Yajun Wang, Xiaoling Ren, Guocheng Zhang, Yuanbin Shi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Pediatrics
medicine.medical_specialty Allergy Breastfeeding RJ1-570 Lower respiratory tract infection 03 medical and health sciences 0302 clinical medicine Wheezy bronchitis Risk Factors 030225 pediatrics Humans Medicine 030212 general & internal medicine Family history Respiratory Tract Infections Respiratory Sounds Retrospective Studies Respiratory tract infections Wheezing business.industry Infant medicine.disease Recombinant human interferon α1b Bronchiolitis Viral pneumonia Pediatrics Perinatology and Child Health Female Interferons business |
Zdroj: | Jornal de Pediatria, Volume: 97, Issue: 6, Pages: 617-622, Published: 06 DEC 2021 Jornal de Pediatria, Vol 97, Iss 6, Pp 617-622 (2021) Jornal de Pediatria v.97 n.6 2021 Jornal de Pediatria Sociedade Brasileira de Pediatria (SBP) instacron:SBPE |
Popis: | Objective: To investigate the impact of recombinant human interferon α1b (rhIFNα1b) treatment in infants hospitalized with lower respiratory tract infections on subsequent wheezing. Methods: The clinical data of infants (n = 540) with viral pneumonia, wheezy bronchitis, or bronchiolitis hospitalized in 19 Chinese hospitals from June 2009 to June 2015 were retrospectively analyzed. The parameters relevant to wheezing episodes within the last year were collected by telephone and questionnaires. The rhIFNα1b treatment group (n = 253) and control group (n = 287) were compared in terms of wheezing episodes within the last year. Moreover, the wheezing group (95 cases) and non-wheezing group (445 cases) were compared. Results: Out of 540 cases, 95 (17.6%) experienced wheezing episodes, 13.8% (35/253) cases treated with rhIFNα1b, and 20.9% (60/287) cases without rhIFNα1b experienced wheezing episodes within the last year. The rhIFNα1b treatment significantly improved wheezing episodes within the last year, compared with the control peers (p = 0.031). Single-factor regression showed statistically significant differences between the wheezing and non-wheezing groups in terms of age, rhIFNα1b use, childhood and family history of allergy, housing situation, and feeding history (p < 0.05). Binary logistic regression showed a childhood history of allergy (OR = 2.14, p = 0.004), no rhIFNα1b use (OR = 1.70, p = 0.028), and living in a crowded house (OR = 1.92, p = 0.012) might be risk factors of subsequent wheezing. Accordingly, breastfeeding (OR = 0.44, p = 0.008) and hospitalization age of 1-year-old (OR = 0.58, p = 0.024) were protective factors. Conclusions: Early use of rhIFNα1b in infants hospitalized with lower respiratory tract infections and breastfeeding could prevent subsequent wheezing. Living in a crowded house could promote subsequent wheezing. |
Databáze: | OpenAIRE |
Externí odkaz: |